semax mastery course
Unit 2 of 11
neuropeptide pharmacology
how ACTH fragments work on the brain without triggering cortisol
fragment pharmacology is the foundation
Semax derives its effects from the ACTH(4-10) fragment, which retains the cognitive and neuroprotective properties of full ACTH while completely lacking the hormonal activity that drives cortisol release. understanding this separation is the key to understanding the molecule and why it does not disturb the HPA axis.
ACTH fragment map
explore the interactive visualization for this unit.
ACTH fragment map
key numbers
quick reference for this unit's core data.
ACTH(4-10)
the cognitive fragment -- positions 4 through 10 of the 39-amino-acid ACTH hormone
0 cortisol
cortisol levels remain unchanged -- the fragment lacks MC2R binding residues
1,800+ genes
genome-wide expression changes in ischemic brain tissue after Semax treatment
>60x stability
PGP extension increases half-life from ~3 minutes to several hours
Semax's primary molecular target remains unidentified. The broad transcriptional effects suggest an upstream mechanism, but the exact receptor or binding site has not been confirmed with modern target-deconvolution techniques.
key terms
definitions for this unit.
A
adrenocorticotropic hormone -- a 39-amino-acid peptide from the anterior pituitary that stimulates cortisol release from the adrenal cortex via the MC2R receptor. Semax derives from positions 4-10 of this hormone, retaining cognitive effects while lacking the hormonal signaling residues at positions 1-3.
M
melanocortin 2 receptor -- expressed on adrenal cortical cells, this is the receptor through which full ACTH triggers cortisol synthesis. it requires ACTH positions 1-3 for binding. Semax completely lacks these residues, which is why it has zero hormonal activity.
P
Pro-Gly-Pro -- the C-terminal tripeptide engineered onto ACTH(4-10) by Russian researchers to increase enzymatic stability. proline residues resist aminopeptidase and carboxypeptidase attack. PGP itself is a collagen fragment with potential anti-inflammatory properties via the CXCR2 receptor.
H
hypothalamic-pituitary-adrenal axis -- the body's central stress response system that controls cortisol release. full ACTH activates this axis. Semax's ACTH(4-10) fragment operates completely independently of the HPA axis, producing cognitive effects without engaging the stress hormone cascade.
P
the minimum structural features of a molecule required for biological activity. for Semax, the minimum cognitive pharmacophore is the ACTH(4-7) tetrapeptide (Met-Glu-His-Phe), with the His-Phe dipeptide being the absolute minimum for any detectable activity.
neuropeptide pharmacology -- the simple version
why a fragment of a stress hormone makes you think better without raising cortisol.
Your body makes a 39-amino-acid hormone called ACTH that tells the adrenal glands to release cortisol (a stress hormone). But researchers discovered that a tiny fragment of ACTH -- just amino acids 4 through 10 -- can improve attention, learning, and memory without touching cortisol at all. This works because the part of ACTH that triggers cortisol (amino acids 1-3) was left out. Semax is built from this cognitive fragment with a protective tail (Pro-Gly-Pro) added to keep it from being destroyed by enzymes in the body within minutes. The result is a molecule that borrows the brain-boosting properties of a natural hormone while completely avoiding its hormonal side effects. Its exact molecular target in the brain is still being investigated, but it triggers changes in over 1,800 genes related to immunity, blood vessel health, and neuronal survival.
A
Cortisol release requires ACTH to bind the melanocortin 2 receptor (MC2R) on adrenal cortical cells. MC2R demands ACTH amino acids 1-3 for binding. The ACTH(4-10) fragment that forms Semax's core completely lacks these residues, giving it essentially zero MC2R affinity. This is not a partial reduction -- it is a complete disconnection from the HPA (hypothalamic-pituitary-adrenal) stress axis. Clinical measurements confirm unchanged cortisol levels during Semax treatment, meaning the cognitive and neuroprotective effects operate through an entirely separate pathway from the hormone's endocrine function.
advanced: the unknown primary target problem
Despite decades of research, Semax's primary molecular target has not been identified with modern target-deconvolution techniques. While it is derived from ACTH, the ACTH(4-10) fragment shows minimal direct binding to melanocortin receptors (MC1R-MC5R) at clinically relevant concentrations. Genome-wide transcriptional analysis reveals over 1,800 gene expression changes spanning immune, vascular, and neuronal survival pathways -- a breadth suggesting an upstream mechanism rather than a single receptor interaction. Some researchers hypothesize uncharacterized melanocortin-like receptors or allosteric modulation of known receptors, but neither has been confirmed experimentally.
advanced: fragment pharmacology as a design principle
The idea that a hormone fragment can retain some activities while losing others is not unique to ACTH. Many neuropeptides have active fragments with distinct pharmacological profiles from the parent molecule. What made ACTH(4-10) especially useful was that it kept the desirable cognitive effects while completely shedding the undesirable cortisol-releasing activity. David de Wied demonstrated this separation in the 1960s-70s using hypophysectomized rats, proving cognitive improvement was independent of adrenal function. Soviet researchers then systematically mapped structure-activity relationships, identifying ACTH(4-7) (Met-Glu-His-Phe) as the minimum cognitive tetrapeptide before adding PGP for stability.
ACTH's behavioral and cognitive fragment activity is the historical anchor for this entire molecular family -- the cortisol-releasing piece (positions 1-3, which bind MC2R on the adrenal cortex) was deliberately excluded. By starting at residue 4, researchers kept the cognitive pharmacophore while shedding the endocrine signal, which is why Semax has no measurable HPA-axis effect despite being an ACTH analog.
from ACTH discovery to clinical drug
how fragment pharmacology led to Semax development over three decades.
1960s
fragment discovery -- David de Wied at Utrecht University demonstrated that ACTH(4-10) improved passive avoidance learning in hypophysectomized rats, proving cognitive effects are independent of adrenal function and cortisol.
1970s-80s
Soviet mapping -- researchers at the Institute of Molecular Genetics systematically tested truncated ACTH fragments. identified ACTH(4-7) as the minimum cognitive fragment and mapped structure-activity relationships across dozens of analogs.
early 1980s
PGP stabilization -- Nikolai Myasoedov and Isaak Ashmarin developed the Semax heptapeptide by adding Pro-Gly-Pro to ACTH(4-10). this increased the half-life from minutes to hours, creating a viable intranasal drug candidate.
late 1990s
clinical approval -- the Russian Ministry of Health approved Semax for ischemic stroke, dyscirculatory encephalopathy, and optic nerve atrophy based on clinical trial data from multiple Russian institutions.
where this has been studied
the lineage of evidence behind ACTH-fragment pharmacology -- mostly Dutch and Russian work with limited Western replication.
de Wied lab (Utrecht)
David de Wied's group at Utrecht University ran the foundational 1970s-80s work showing that ACTH(4-10) and related fragments improved passive-avoidance and active-avoidance learning in hypophysectomized rats. These experiments established that the cognitive effects were dissociable from cortisol release and gave the field its first proof that a hormone fragment could retain CNS activity without endocrine activity.
Soviet structure-activity mapping
Soviet groups systematically truncated and substituted ACTH fragments through the 1970s and 1980s, narrowing the cognitive pharmacophore down to the Met-Glu-His-Phe tetrapeptide and confirming Pro-Gly-Pro as the stabilizing tail of choice. These structure-activity studies sit behind every modern claim about which residues matter and which can be replaced.
Myasoedov / IMG Semax design
Nikolai Myasoedov's laboratory at the Institute of Molecular Genetics (Russian Academy of Sciences, Moscow) finalized the Semax heptapeptide in the 1990s by appending PGP to ACTH(4-7). The same lab later applied the identical PGP-extension strategy to tuftsin to produce Selank, demonstrating PGP as a general-purpose stabilization template for short regulatory peptides.
Russian Phase III dossier
The late-1990s submission package to the Russian Ministry of Health (MoH) compiled multi-center trial data for ischemic stroke, dyscirculatory encephalopathy, and optic nerve atrophy. This dossier is the basis for Semax's regulatory approval in Russia but has never been republished in Western peer-reviewed form, which is why Western readers see the molecule as under-evidenced even though its registration file is substantial.
three peptide-drug design philosophies
how the Semax (ACTH-derived) and Selank (tuftsin-derived) approach differs from traditional small-molecule peptide drugs.
ACTH-derived (Semax)
- Design philosophy: subtract the endocrine residues, keep the cognitive ones
- Biological starting point: ACTH(4-10), the cognitive fragment of a stress hormone
- Stability strategy: append Pro-Gly-Pro to the C-terminus
- Regulatory pathway: Russian MoH approval; never filed with FDA or EMA
tuftsin-derived (Selank)
- Design philosophy: take an immune signal, extend it to gain CNS activity
- Biological starting point: tuftsin, a 4-residue IgG fragment that stimulates phagocytosis
- Stability strategy: same Pro-Gly-Pro tail (shared template with Semax)
- Regulatory pathway: Russian MoH approval for generalized anxiety disorder (2009)
traditional peptide drugs
- Design philosophy: optimize a single-target hormone analog for one receptor
- Biological starting point: usually a full native hormone (GLP-1, somatostatin, oxytocin)
- Stability strategy: D-amino acid swaps, PEGylation, or cyclization
- Regulatory pathway: Western Phase I-III, FDA/EMA approval (semaglutide, octreotide)